Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1975 3
1976 1
1978 1
1980 3
1981 2
1982 3
1983 6
1984 4
1985 2
1986 4
1987 7
1988 2
1989 9
1990 11
1991 3
1992 5
1993 12
1994 15
1995 10
1996 7
1997 17
1998 16
1999 11
2000 19
2001 8
2002 13
2003 20
2004 20
2005 18
2006 16
2007 18
2008 26
2009 21
2010 20
2011 28
2012 38
2013 46
2014 47
2015 54
2016 67
2017 61
2018 70
2019 59
2020 59
2021 81
2022 77
2023 65
2024 32

Text availability

Article attribute

Article type

Publication date

Search Results

978 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Hypertrophic cardiomyopathy 15"
Page 1
Distinct Subgroups in Hypertrophic Cardiomyopathy in the NHLBI HCM Registry.
Neubauer S, Kolm P, Ho CY, Kwong RY, Desai MY, Dolman SF, Appelbaum E, Desvigne-Nickens P, DiMarco JP, Friedrich MG, Geller N, Harper AR, Jarolim P, Jerosch-Herold M, Kim DY, Maron MS, Schulz-Menger J, Piechnik SK, Thomson K, Zhang C, Watkins H, Weintraub WS, Kramer CM; HCMR Investigators. Neubauer S, et al. J Am Coll Cardiol. 2019 Nov 12;74(19):2333-2345. doi: 10.1016/j.jacc.2019.08.1057. J Am Coll Cardiol. 2019. PMID: 31699273 Free PMC article.
BACKGROUND: The HCMR (Hypertrophic Cardiomyopathy Registry) is a National Heart, Lung, and Blood Institute-funded, prospective registry of 2,755 patients with hypertrophic cardiomyopathy (HCM) recruited from 44 sites in 6 countries. OBJECTIVES: The aut …
BACKGROUND: The HCMR (Hypertrophic Cardiomyopathy Registry) is a National Heart, Lung, and Blood Institute-funded, prospective …
Fully Automated Echocardiogram Interpretation in Clinical Practice.
Zhang J, Gajjala S, Agrawal P, Tison GH, Hallock LA, Beussink-Nelson L, Lassen MH, Fan E, Aras MA, Jordan C, Fleischmann KE, Melisko M, Qasim A, Shah SJ, Bajcsy R, Deo RC. Zhang J, et al. Circulation. 2018 Oct 16;138(16):1623-1635. doi: 10.1161/CIRCULATIONAHA.118.034338. Circulation. 2018. PMID: 30354459 Free PMC article.
Results were evaluated through comparison to manual segmentation and measurements from 8666 echocardiograms obtained during the routine clinical workflow. Finally, we developed models to detect 3 diseases: hypertrophic cardiomyopathy, cardiac amyloid, and pulmonary …
Results were evaluated through comparison to manual segmentation and measurements from 8666 echocardiograms obtained during the routine clin …
A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD).
O'Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C, Biagini E, Gimeno JR, Limongelli G, McKenna WJ, Omar RZ, Elliott PM; Hypertrophic Cardiomyopathy Outcomes Investigators. O'Mahony C, et al. Eur Heart J. 2014 Aug 7;35(30):2010-20. doi: 10.1093/eurheartj/eht439. Epub 2013 Oct 14. Eur Heart J. 2014. PMID: 24126876
AIMS: Hypertrophic cardiomyopathy (HCM) is a leading cause of sudden cardiac death (SCD) in young adults. ...These predictors were included in the final model to estimate individual probabilities of SCD at 5 years. ...
AIMS: Hypertrophic cardiomyopathy (HCM) is a leading cause of sudden cardiac death (SCD) in young adults. ...These predicto …
Randomized Trial of Metoprolol in Patients With Obstructive Hypertrophic Cardiomyopathy.
Dybro AM, Rasmussen TB, Nielsen RR, Andersen MJ, Jensen MK, Poulsen SH. Dybro AM, et al. J Am Coll Cardiol. 2021 Dec 21;78(25):2505-2517. doi: 10.1016/j.jacc.2021.07.065. J Am Coll Cardiol. 2021. PMID: 34915981 Free article. Clinical Trial.
BACKGROUND: The use of beta-adrenergic receptor blocking agents in symptomatic patients with obstructive hypertrophic cardiomyopathy (HCM) rests on clinical experience and observational cohort studies. ...Maximum exercise capacity remained unchanged. (The Eff …
BACKGROUND: The use of beta-adrenergic receptor blocking agents in symptomatic patients with obstructive hypertrophic cardiomyopat …
Computational prediction of protein subdomain stability in MYBPC3 enables clinical risk stratification in hypertrophic cardiomyopathy and enhances variant interpretation.
Thompson AD, Helms AS, Kannan A, Yob J, Lakdawala NK, Wittekind SG, Pereira AC, Jacoby DL, Colan SD, Ashley EA, Saberi S, Ware JS, Ingles J, Semsarian C, Michels M, Mazzarotto F, Olivotto I, Ho CY, Day SM. Thompson AD, et al. Genet Med. 2021 Jul;23(7):1281-1287. doi: 10.1038/s41436-021-01134-9. Epub 2021 Mar 29. Genet Med. 2021. PMID: 33782553 Free PMC article.
PURPOSE: Variants in MYBPC3 causing loss of function are the most common cause of hypertrophic cardiomyopathy (HCM). However, a substantial number of patients carry missense variants of uncertain significance (VUS) in MYBPC3. ...METHODS: Among 7,963 patients in the …
PURPOSE: Variants in MYBPC3 causing loss of function are the most common cause of hypertrophic cardiomyopathy (HCM). However, …
Exercise and myocardial injury in hypertrophic cardiomyopathy.
Cramer GE, Gommans DHF, Dieker HJ, Michels M, Verheugt F, de Boer MJ, Bakker J, Fouraux MA, Timmermans J, Kofflard M, Brouwer M. Cramer GE, et al. Heart. 2020 Aug;106(15):1169-1175. doi: 10.1136/heartjnl-2019-315818. Epub 2020 Jan 30. Heart. 2020. PMID: 32001622 Free PMC article.
OBJECTIVE: Troponin and high signal intensity on T2-weighted (HighT2) cardiovascular magnetic resonance imaging (CMRi) are both markers of myocardial injury in hypertrophic cardiomyopathy (HCM). The interplay between exercise and disease development remains uncertai …
OBJECTIVE: Troponin and high signal intensity on T2-weighted (HighT2) cardiovascular magnetic resonance imaging (CMRi) are both markers of m …
Patterns of Replacement Fibrosis in Hypertrophic Cardiomyopathy.
Liu J, Zhao S, Yu S, Wu G, Wang D, Liu L, Song J, Zhu Y, Kang L, Wang J, Song L. Liu J, et al. Radiology. 2022 Feb;302(2):298-306. doi: 10.1148/radiol.2021210914. Epub 2021 Nov 2. Radiology. 2022. PMID: 34726536
Background Myocardial replacement fibrosis is one of the major histologic features of hypertrophic cardiomyopathy (HCM), but its characteristics have not been well delineated. ...Cox analysis indicated that both the global extent of LGE (adjusted hazard ratio = 1.68 …
Background Myocardial replacement fibrosis is one of the major histologic features of hypertrophic cardiomyopathy (HCM), but i …
Mitral Annular Calcification in Obstructive Hypertrophic Cardiomyopathy: Prevalence and Outcomes.
Patlolla SH, Schaff HV, Nishimura RA, Geske JB, Lahr BD, Lee AT, Eleid MF, Ommen SR, Dearani JA. Patlolla SH, et al. Ann Thorac Surg. 2022 Nov;114(5):1679-1687. doi: 10.1016/j.athoracsur.2021.09.077. Epub 2021 Nov 22. Ann Thorac Surg. 2022. PMID: 34822847 Review.
BACKGROUND: The prevalence and clinical impact of mitral annular calcification (MAC) in patients with obstructive hypertrophic cardiomyopathy (HCM) are largely unknown. METHODS: We reviewed 2113 HCM patients who underwent septal myectomy from January 2000 to April 2 …
BACKGROUND: The prevalence and clinical impact of mitral annular calcification (MAC) in patients with obstructive hypertrophic car …
Changing Demographics in Hypertrophic Cardiomyopathy and Implications for Management: Clinical Research.
Maron BJ, Rowin EJ, Ambe SP, Maron MS. Maron BJ, et al. Am J Med. 2022 Oct;135(10):1244-1246. doi: 10.1016/j.amjmed.2022.05.006. Epub 2022 May 29. Am J Med. 2022. PMID: 35649468
PURPOSE: This study aimed to determine whether clinicians are encountering a phenotype of hypertrophic cardiomyopathy that is evolving from the disease recognized several years ago. METHODS: A total of 3161 consecutive patients with established hypertrophic …
PURPOSE: This study aimed to determine whether clinicians are encountering a phenotype of hypertrophic cardiomyopathy that is …
Improved Diagnostic Criteria for Apical Hypertrophic Cardiomyopathy.
Hughes RK, Shiwani H, Rosmini S, Augusto JB, Burke L, Jiang Y, Pierce I, Joy G, Castelletti S, Orini M, Kellman P, Xue H, Lopes LR, Mohiddin S, Treibel T, Manisty C, Captur G, Davies R, Moon JC. Hughes RK, et al. JACC Cardiovasc Imaging. 2024 May;17(5):501-512. doi: 10.1016/j.jcmg.2023.07.012. Epub 2023 Oct 11. JACC Cardiovasc Imaging. 2024. PMID: 37831014
BACKGROUND: There is no acceptable maximum wall thickness (MWT) threshold for diagnosing apical hypertrophic cardiomyopathy (ApHCM), with guidelines referring to 15 mm MWT for all hypertrophic cardiomyopathy subtypes. ...A clinically defined dis …
BACKGROUND: There is no acceptable maximum wall thickness (MWT) threshold for diagnosing apical hypertrophic cardiomyopathy (A …
978 results